This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, T. Y. Articles by Shong, Y. K. Search for Related Content PubMed PubMed Citation Articles by Kim, T. Y. Articles by Shong, Y. K. Related Collections Thyroid Endocrine Oncology

Serum Thyroglobulin Levels at the Time of ¹³¹I Remnant Ablation Just after Thyroidectomy Are Useful for Early Prediction of Clinical Recurrence in Low-Risk Patients with Differentiated Thyroid Carcinoma

Departments of Internal Medicine (T.Y.K., W.B.K., Y.K.S.), Nuclear Medicine (J.S.R., J.S.Y.), and Surgery (S.C.K., S.J.H.), Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Korea; and Department of Internal Medicine (E.S.K.), Ulsan University Hospital, Ulsan 682-060, Korea

Address all correspondence and requests for reprints to: Young Kee Shong, M.D., Ph.D., Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-dong, Songpa-gu, Seoul 138-736, Korea. E-mail: ykshong{at}amc.seoul.kr.

We investigated whether serum thyroglobulin (Tg) measured at the time of remnant ablation (ablation-Tg) could be a prognostic indicator complementary to serum Tg levels at the time of the first diagnostic whole-body scan (WBS) after thyroid hormone withdrawal (control-Tg; approximately 6–12 months after ablation-Tg) and whether ablation-Tg could predict the persistence or recurrence of disease in low-risk patients with differentiated thyroid carcinoma.

Patients with differentiated thyroid carcinoma (n = 268) treated with total or near-total thyroidectomy followed by immediate ¹³¹I remnant ablation were studied. Patients with anti-Tg autoantibodies and those showing evidence of extracervical metastases were excluded. Two patients showing remnant uptake on follow-up diagnostic WBS received a second ablation. We found significant correlation between ablation-Tg and control-Tg levels; 114 of 143 patients (80%) with ablation-Tg greater than 2 µg/liter showed detectable (1 µg/liter) control-Tg, and 70 of 125 (56%) patients with ablation-Tg 2 µg/liter or less showed undetectable (<1 µg/liter) control-Tg [odds ratio 5.1, 95% confidence interval (CI) 3.0–8.9, P < 0.001]. When the 268 patients were followed up for a mean period of 5.7 ± 1.4 yr (range 2.8–8.3 yr), 35 (13%) had recurrences; 73 (27%) were classified as "Tg positive, no evidence of disease"; and 160 (60%) showed complete remission. Of 143 patients with ablation-Tg greater than 2 µg/liter, recurrence was observed in 33 cases (23%); "Tg positive, no evidence of disease," was observed in 52 cases (36%); and complete remission was observed in 58 cases (41%). Of 125 patients with ablation-Tg 2 µg/liter or less, two patients (2%) showed recurrence during the follow-up; 21 patients (17%) were regarded as "Tg positive, no evidence of disease"; and 102 patients (81%) showed complete remission. The positive predictive value for recurrence in patients having ablation-Tg greater than 2 µg/liter was found to be 23.1% (33 of 143 patients, 95% CI 16.4–30.8%). The negative predictive value for recurrence in patients having ablation-Tg 2 µg/liter or less was found to be 98.4% (123 of 125 patients, 95% CI 94.4–99.8%).

These data indicate that serum Tg levels measured at the time of immediate postoperative ¹³¹I remnant ablation correlated well with serum Tg levels at the time of the initial diagnostic WBS and had a complementary role for predicting persistence or recurrence of disease in the earliest postoperative period.

This article has been cited by other articles:

				Y. Gao, H. Lu, Z. Yuan, and R. Zhu Tumor Markers in Thyroid Carcinoma With Pulmonary Metastases After Thyroidectomy Lab Med, January 1, 2009; 40(1): 30 - 34. [Abstract] [Full Text] [PDF]

				W. G. Kim, J. H. Yoon, W. B. Kim, T. Y. Kim, E. Y. Kim, J. M. Kim, J.-S. Ryu, G. Gong, S. J. Hong, and Y. K. Shong Change of Serum Antithyroglobulin Antibody Levels Is Useful for Prediction of Clinical Recurrence in Thyroglobulin-Negative Patients with Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4683 - 4689. [Abstract] [Full Text] [PDF]

				N. A. Johnson and M. E. Tublin Postoperative Surveillance of Differentiated Thyroid Carcinoma: Rationale, Techniques, and Controversies Radiology, November 1, 2008; 249(2): 429 - 444. [Abstract] [Full Text] [PDF]

				D. Handkiewicz-Junak, J. Wloch, J. Roskosz, J. Krajewska, A. Kropinska, L. Pomorski, A. Kukulska, A. Prokurat, Z. Wygoda, and B. Jarzab Total Thyroidectomy and Adjuvant Radioiodine Treatment Independently Decrease Locoregional Recurrence Risk in Childhood and Adolescent Differentiated Thyroid Cancer J. Nucl. Med., June 1, 2007; 48(6): 879 - 888. [Abstract] [Full Text] [PDF]

				R. B T Verkooijen, D. Rietbergen, J. W Smit, J. A Romijn, and M. P M Stokkel A new functional parameter measured at the time of ablation that can be used to predict differentiated thyroid cancer recurrence during follow-up Eur. J. Endocrinol., January 1, 2007; 156(1): 41 - 47. [Abstract] [Full Text] [PDF]

				F. Pacini, M. Schlumberger, C. Harmer, G. G Berg, O. Cohen, L. Duntas, F. Jamar, B. Jarzab, E. Limbert, P. Lind, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report Eur. J. Endocrinol., November 1, 2005; 153(5): 651 - 659. [Abstract] [Full Text] [PDF]